The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
- PMID: 32073443
- PMCID: PMC7431369
- DOI: 10.1097/MEG.0000000000001681
The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
Abstract
Background: Current guidelines recommend surveillance for hepatocellular carcinoma (HCC) in high-risk patients. This high risk is defined by the presence of cirrhosis. However, HCC due to underlying nonalcoholic steatohepatitis (NASH), even without progressing to cirrhosis, is a rising concern. Hence, we aimed to determine the association of HCC with NASH using a large national database.
Methods: A cross-sectional study was performed using the 2012 National Inpatient Sample. The study group was all adult patients' age 18-90 years who have a diagnosis of NASH which was identified using the International Classification of Diseases 9th version (ICD-9) codes. The control group included the rest of adult individuals without discharge records of NASH. We identified the diagnosis of HCC in both study and control groups using the ICD-9 codes. We calculated the association between NASH and HCC using univariable and multivariate logistic regression.
Results: Totally, 30 712 524 hospitalizations were included in our study. This cohort included 218 950 patients with NASH (study group) and 30 493 574 patients without NASH (control group). The study group patients aged 57.3 ± 0.10 years (59.4% females) comparing to 54.5 ± 0.11 years (57.1% female) in the control group. HCC prevalence in subjects with NASH was 0.50% [95% confidence interval (CI): 0.41-0.59] compared to 0.21% (95% CI: 0.20-0.23) in subjects without NASH (P < 0.001). After adjusting for age, gender, smoking, alcohol use, obesity, hepatitis C virus, hepatitis B virus, hemochromatosis, HIV, cirrhosis and the modified comorbidity index, subjects with NASH were 60% more likely to have HCC than those without NASH (adjusted odds ratio: 1.6, 95% CI: 1.4-1.9, P < 0.001).
Conclusion: Our study showed that NASH patients are 60% more likely to develop HCC compared with patients without NASH. Close monitoring and even periodical surveillance might be needed.
Conflict of interest statement
Conflicts of Interest
The authors have no conflict of interest to disclose.
Figures
Similar articles
-
Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.BMC Med. 2019 May 20;17(1):95. doi: 10.1186/s12916-019-1321-x. BMC Med. 2019. PMID: 31104631 Free PMC article.
-
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7. Dig Dis Sci. 2015. PMID: 26250831
-
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.Gastroenterology. 2017 Apr;152(5):1090-1099.e1. doi: 10.1053/j.gastro.2017.01.003. Epub 2017 Jan 11. Gastroenterology. 2017. PMID: 28088461 Free PMC article.
-
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther. 2018 Oct;48(7):696-703. doi: 10.1111/apt.14937. Epub 2018 Aug 22. Aliment Pharmacol Ther. 2018. PMID: 30136293 Free PMC article.
-
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.World J Gastroenterol. 2023 Jan 14;29(2):286-309. doi: 10.3748/wjg.v29.i2.286. World J Gastroenterol. 2023. PMID: 36687124 Free PMC article. Review.
Cited by
-
Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.Hepat Oncol. 2020 Jul 21;7(3):HEP27. doi: 10.2217/hep-2020-0024. Hepat Oncol. 2020. PMID: 32774837 Free PMC article. Review.
-
Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?J Hepatocell Carcinoma. 2022 May 5;9:379-387. doi: 10.2147/JHC.S364742. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 35547829 Free PMC article. Review.
-
The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis.Interact J Med Res. 2023 Jul 19;12:e40653. doi: 10.2196/40653. Interact J Med Res. 2023. PMID: 37467012 Free PMC article. Review.
-
Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.J Hepatocell Carcinoma. 2022 Jun 1;9:477-496. doi: 10.2147/JHC.S344559. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 35673598 Free PMC article. Review.
-
Farnesoid X receptor: a potential therapeutic target in multiple organs.Histol Histopathol. 2020 Dec;35(12):1403-1414. doi: 10.14670/HH-18-301. Epub 2021 Jan 4. Histol Histopathol. 2020. PMID: 33393073 Review.
References
-
- Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36(6):1349–1354. - PubMed
-
- Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17 Suppl:S186–S190. - PubMed
-
- Bugianesi E Non-alcoholic Steatohepatitis and Cancer. Clin Liver Dis. 2007;11(1):191–207. - PubMed
-
- Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51(5):1820–1832. - PubMed
-
- Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13(4):631–647. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical